Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | KMT5A | Q9NQR1 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
| ▸ | WHR1 | P49842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820037 | 0.82 | HRH4 (0.40) | HRH4RECQLSMN1; SMN2SUV39H2 | |
| SCHEMBL6919803 | 0.76 | EHMT2 (0.45) | SLC2A1NMT1SPIN1EHMT2EHMT1 | |
| SCHEMBL6609401 | 0.74 | EHMT2 (0.41) | SLC2A1SPIN1EHMT2EHMT1HRH4 | |
| SCHEMBL6863012 | 0.73 | SLC6A2 (0.34) | SLC2A1NMT1SPIN1EHMT2EHMT1 | |
| SCHEMBL6016881 | 0.71 | MAPK1 (0.36) | SLC2A1SPIN1EHMT2EHMT1HRH4 | |
| SCHEMBL4838341 | 0.71 | MAPT (0.43) | EHMT2EHMT1RECQLBCL6 | |
| SCHEMBL5424507 | 0.68 | SLC6A2 (0.40) | SLC2A1NMT1SPIN1 | |
| SCHEMBL5556168 | 0.68 | SMN1; SMN2 (0.41) | HRH4RECQLBCL6SMN1; SMN2 | |
| SCHEMBL6862314 | 0.67 | KDM1A (0.39) | NMT1EHMT2EHMT1KMT5ABCL6 | |
| SCHEMBL5033412 | 0.67 | EHMT2 (0.38) | SLC2A1NMT1SPIN1EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | claimed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7265114-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-7112587-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-11-11 | — | — | US | disclosed |
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SLC2A1 481/4885NMT1 2486/4885SPIN1 4497/4885 |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | SLC2A1 636/4885NMT1 2773/4885SPIN1 4480/4885 |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SLC2A1 481/4885NMT1 2486/4885SPIN1 4497/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | SLC2A1 481/4885NMT1 2486/4885SPIN1 4497/4885 |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | ENGASE, LIPG, GPI | SLC2A1 542/4885NMT1 560/4885SPIN1 3414/4885 |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
| US-20040077648-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SLC2A1 616/4885NMT1 1911/4885SPIN1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.